A Phase 1 clinical trial evaluating the safety and preliminary efficacy of Adicet Bio’s CAR T-cell therapy ADI-001 in…
Articles by Andrea Lobo, PhD
Patterns of lung damage on CT scans may help predict disease outcomes in people with ANCA-associated vasculitis (AAV) and…
A European Medicines Agency (EMA) committee has issued a positive opinion recommending the approval of Fasenra (benralizumab) as an…
Rituximab may be associated with a higher risk of serious adverse events, particularly infections, in people with granulomatosis with…
ANCA-associated vasculitis (AAV) patients treated with rituximab are up to four times more likely to develop hypogammaglobulinemia (HGG),…
Treatment with rituximab is superior to cyclophosphamide at inducing disease remission in people with granulomatosis with polyangiitis (GPA),…
About a quarter of people with granulomatosis with polyangiitis (GPA)Â or microscopic polyangiitis (MPA) under maintenance treatment with rituximab experience…
People with ANCA-associated vasculitis (AAV) have an 83% higher risk of developing cardiovascular and cerebrovascular diseases (CCVD) relative to…
Researchers have identified a set of clinical red flags that could help detect eosinophilic granulomatosis with polyangiitis (EGPA), the rarest…
Eye symptoms related to ANCA-associated vasculitis (AAV) are most common among those with granulomatosis with polyangiitis (GPA), affecting more…